Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Pulse-chase SILAC-based analyses reveal selective over-synthesis and rapid turnover of mitochondrial protein components of respiratory complexes.

Bogenhagen DF, Haley JD.

J Biol Chem. 2020 Jan 23. pii: jbc.RA119.011791. doi: 10.1074/jbc.RA119.011791. [Epub ahead of print]

PMID:
31974161
2.

Novel replisome-associated proteins at cellular replication forks in EBV-transformed B lymphocytes.

Xu H, Perez RD, Frey TR, Burton EM, Mannemuddhu S, Haley JD, McIntosh MT, Bhaduri-McIntosh S.

PLoS Pathog. 2019 Dec 16;15(12):e1008228. doi: 10.1371/journal.ppat.1008228. eCollection 2019 Dec.

3.

Decoupling of Nrf2 Expression Promotes Mesenchymal State Maintenance in Non-Small Cell Lung Cancer.

Haley JA, Ruiz CF, Montal ED, Wang D, Haley JD, Girnun GD.

Cancers (Basel). 2019 Oct 2;11(10). pii: E1488. doi: 10.3390/cancers11101488.

4.

Correction: PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.

Salama MF, Liu M, Clarke CJ, Espaillat MP, Haley JD, Jin T, Wang D, Obeid LM, Hannun YA.

Oncogene. 2019 Nov;38(48):7366. doi: 10.1038/s41388-019-1019-8.

PMID:
31576014
5.

PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation.

Salama MF, Liu M, Clarke CJ, Espaillat MP, Haley JD, Jin T, Wang D, Obeid LM, Hannun YA.

Oncogene. 2019 Nov;38(48):7311-7328. doi: 10.1038/s41388-019-0950-z. Epub 2019 Aug 16. Erratum in: Oncogene. 2019 Oct 1;:.

PMID:
31420605
6.

Inhibition of phosphoenolpyruvate carboxykinase blocks lactate utilization and impairs tumor growth in colorectal cancer.

Montal ED, Bhalla K, Dewi RE, Ruiz CF, Haley JA, Ropell AE, Gordon C, Haley JD, Girnun GD.

Cancer Metab. 2019 Aug 1;7:8. doi: 10.1186/s40170-019-0199-6. eCollection 2019.

7.

Pulse SILAC Approaches to the Measurement of Cellular Dynamics.

Snider J, Wang D, Bogenhagen DF, Haley JD.

Adv Exp Med Biol. 2019;1140:575-583. doi: 10.1007/978-3-030-15950-4_34. Review.

PMID:
31347072
8.

Imaging with mass spectrometry, the next frontier in sphingolipid research? A discussion on where we stand and the possibilities ahead.

Luberto C, Haley JD, Del Poeta M.

Chem Phys Lipids. 2019 Mar;219:1-14. doi: 10.1016/j.chemphyslip.2019.01.001. Epub 2019 Jan 11. Review.

PMID:
30641043
9.

De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer.

Singh A, Ruiz C, Bhalla K, Haley JA, Li QK, Acquaah-Mensah G, Montal E, Sudini KR, Skoulidis F, Wistuba II, Papadimitrakopoulou V, Heymach JV, Boros LG, Gabrielson E, Carretero J, Wong KK, Haley JD, Biswal S, Girnun GD.

FASEB J. 2018 Jun 15:fj201800204. doi: 10.1096/fj.201800204. [Epub ahead of print]

10.

Kinetics and Mechanism of Mammalian Mitochondrial Ribosome Assembly.

Bogenhagen DF, Ostermeyer-Fay AG, Haley JD, Garcia-Diaz M.

Cell Rep. 2018 Feb 13;22(7):1935-1944. doi: 10.1016/j.celrep.2018.01.066.

11.

Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages.

Wang D, Haley JD, Thompson P.

BMC Cancer. 2017 Dec 6;17(1):830. doi: 10.1186/s12885-017-3832-1.

12.

Examining the aggregation behavior of polymer grafted nanoparticles using molecular simulation and theory.

Haley JD, Iacovella CR, Cummings PT, McCabe C.

J Chem Phys. 2015 Aug 7;143(5):054904. doi: 10.1063/1.4927819.

PMID:
26254667
13.

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models.

Haley JA, Haughney E, Ullman E, Bean J, Haley JD, Fink MY.

Front Oncol. 2014 Dec 8;4:344. doi: 10.3389/fonc.2014.00344. eCollection 2014.

14.

A systems view of epithelial-mesenchymal transition signaling states.

Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD.

Clin Exp Metastasis. 2011 Feb;28(2):137-55. doi: 10.1007/s10585-010-9367-3. Epub 2010 Dec 31.

15.

AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment.

Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS.

Cancer Res. 2010 Oct 1;70(19):7360-4. doi: 10.1158/0008-5472.CAN-10-1208. Epub 2010 Sep 7.

16.

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS.

Cancer Res. 2008 Oct 15;68(20):8322-32. doi: 10.1158/0008-5472.CAN-07-6720.

17.

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.

Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.

Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4. Epub 2008 Aug 12.

PMID:
18696232
18.

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.

Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, Eyzaguirre A, Rosenfeld-Franklin M, Gibson NW, Miglarese M, Epstein D, Iwata KK, Haley JD.

Clin Exp Metastasis. 2008;25(6):685-93. doi: 10.1007/s10585-007-9121-7. Epub 2008 Jan 31. Review.

19.

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.

Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, Haley JD.

Mol Cancer Ther. 2007 Feb;6(2):532-41.

20.

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.

Mol Cancer Ther. 2006 Nov;5(11):2676-84.

22.

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.

Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX.

Cancer Res. 2006 Aug 15;66(16):8163-71.

23.

Peptide, domain, and DNA affinity selection in the identification and quantitation of proteins from complex biological samples.

Petti F, Thomson S, Haley JD.

Anal Biochem. 2006 Sep 1;356(1):1-11. Epub 2006 Jun 9. Review. No abstract available.

PMID:
16797468
24.

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD.

Cancer Res. 2005 Oct 15;65(20):9455-62.

25.

Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity.

Mason LJ, Lambrianides A, Haley JD, Manson JJ, Latchman DS, Isenberg DA, Rahman A.

Arthritis Res Ther. 2005;7(5):R971-83. Epub 2005 Jun 10.

26.

Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930.

Petti F, Thelemann A, Kahler J, McCormack S, Castaldo L, Hunt T, Nuwaysir L, Zeiske L, Haack H, Sullivan L, Garton A, Haley JD.

Mol Cancer Ther. 2005 Aug;4(8):1186-97.

27.

Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.

Thelemann A, Petti F, Griffin G, Iwata K, Hunt T, Settinari T, Fenyo D, Gibson N, Haley JD.

Mol Cell Proteomics. 2005 Apr;4(4):356-76. Epub 2005 Jan 17.

28.

Identification and characterization of mechanistically distinct inducers of gamma-globin transcription.

Haley JD, Smith DE, Schwedes J, Brennan R, Pearce C, Moore C, Wang F, Petti F, Grosveld F, Jane SM, Noguchi CT, Schechter AN.

Biochem Pharmacol. 2003 Nov 1;66(9):1755-68.

29.

A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs.

Giles IP, Haley JD, Nagl S, Isenberg DA, Latchman DS, Rahman A.

Semin Arthritis Rheum. 2003 Feb;32(4):246-65. Review.

PMID:
12621590
30.

The gene expression sequence of radiated mucosa in an animal mucositis model.

Sonis ST, Scherer J, Phelan S, Lucey CA, Barron JE, O'Donnell KE, Brennan RJ, Pan H, Busse P, Haley JD.

Cell Prolif. 2002 Aug;35 Suppl 1:93-102.

PMID:
12139712
32.

Oral mucosal permeability and stability of transforming growth factor beta-3 in vitro.

Squier CA, Kremer MJ, Bruskin A, Rose A, Haley JD.

Pharm Res. 1999 Oct;16(10):1557-63.

PMID:
10554097
33.

Identification of Id2 as a globin regulatory protein by representational difference analysis of K562 cells induced to express gamma-globin with a fungal compound.

Holmes ML, Haley JD, Cerruti L, Zhou WL, Zogos H, Smith DE, Cunningham JM, Jane SM.

Mol Cell Biol. 1999 Jun;19(6):4182-90.

34.

Transforming growth factor-beta3 protection of epithelial cells from cycle-selective chemotherapy in vitro.

McCormack ES, Borzillo GV, Ambrosino C, Mak G, Hamablet L, Qu GY, Haley JD.

Biochem Pharmacol. 1997 Apr 25;53(8):1149-59.

PMID:
9175720
35.

Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis.

Sonis ST, Van Vugt AG, Brien JP, Muska AD, Bruskin AM, Rose A, Haley JD.

Oral Oncol. 1997 Jan;33(1):47-54.

PMID:
9192553
37.

Umbilical cord transforming growth factor-beta 3: isolation, comparison with recombinant TGF-beta 3 and cellular localization.

Stewart AA, Haley JD, Qu GY, Stam K, Fenyö D, Chait BT, Marshak DR, Ng AY, Marley G, Iwata KK.

Growth Factors. 1996;13(1-2):87-98.

PMID:
8962723
38.

Physical and biological characterization of a growth-inhibitory activity purified from the neuroepithelioma cell line A673.

Stam K, Stewart AA, Qu GY, Iwata KK, Fenyö D, Chait BT, Marshak DR, Haley JD.

Biochem J. 1995 Jan 1;305 ( Pt 1):87-92.

39.

Gene expression as a target for new drug discovery.

Heguy A, Stewart AA, Haley JD, Smith DE, Foulkes JG.

Gene Expr. 1995;4(6):337-44. Review.

40.

Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3.

Sonis ST, Lindquist L, Van Vugt A, Stewart AA, Stam K, Qu GY, Iwata KK, Haley JD.

Cancer Res. 1994 Mar 1;54(5):1135-8.

41.

TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.

Lemoli RM, Strife A, Clarkson BD, Haley JD, Gulati SC.

Exp Hematol. 1992 Dec;20(11):1252-6.

PMID:
1493854
42.

The effects of transforming growth factor beta 3 on the growth of highly enriched hematopoietic progenitor cells derived from normal human bone marrow and peripheral blood.

Strife A, Lambek C, Perez A, Darzynkiewicz Z, Skierski J, Gulati S, Haley JD, ten Dijke P, Iwata KK, Clarkson BD.

Cancer Res. 1991 Sep 15;51(18):4828-36.

44.
45.

Analysis of mammalian fibroblast transformation by normal and mutated human EGF receptors.

Haley JD, Hsuan JJ, Waterfield MD.

Oncogene. 1989 Mar;4(3):273-83.

PMID:
2784850
46.

Loss of three major auto phosphorylation sites in the EGF receptor does not block the mitogenic action of EGF.

Clark S, Cheng DJ, Hsuan JJ, Haley JD, Waterfield MD.

J Cell Physiol. 1988 Mar;134(3):421-8.

PMID:
3258313
47.

Primed synthesis and direct sequencing in the isolation of cDNA clones using short oligonucleotides.

Haley JD.

Methods Mol Biol. 1988;4:307-18. doi: 10.1385/0-89603-127-6:307.

PMID:
21424641
48.

Cosmid library construction.

Haley JD.

Methods Mol Biol. 1988;4:257-83. doi: 10.1385/0-89603-127-6:257.

PMID:
21424638

Supplemental Content

Loading ...
Support Center